Methodological considerations for comparison of brand versus generic versus authorized generic adverse event reports in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)

Eitemau Tebyg

• Comparison of Brand versus Generic Antiepileptic Drug Adverse Event Reporting Rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)
  gan: Rahman, Md. Motiur, et al.
  Cyhoeddwyd: (2017)
• Brand vs. generic adverse event reporting patterns: an authorized generic-controlled evaluation of cardiovascular medications
  gan: Alatawi, Yasser, et al.
  Cyhoeddwyd: (2017)
• Mixed approach retrospective analyses of suicide and suicidal ideation for brand compared with generic central nervous system drugs
  gan: Cheng, Ning, et al.
  Cyhoeddwyd: (2018)
• Comparison of generic-to-brand switchback patterns for generic and authorized generic drugs
  gan: Hansen, Richard A., et al.
  Cyhoeddwyd: (2017)
• Comparison of outcomes following a switch from a brand to an authorized vs. independent generic drug
  gan: Hansen, Richard A., et al.
  Cyhoeddwyd: (2017)